Johnson & Johnson (NYSE:JNJ) released their financial report for the second quarter of 2022, this week, demonstrating strong growth and promising guidance for the rest of the year. Analysts seem to agree, as the consensus rating for JNJ is MODERATE BUY. This rating has remained consistent for at least the past three months.
These same analysts have given JNJ an average price target of $191.50 within the range of $201 and $174. All of these estimates are up, at least 2 percent.
